Michael Schickler - 18 Mar 2026 Form 3 Insider Report for PURPLE BIOTECH LTD. (PPBT)

Reporting relationship: Head of Clinical & Reg Affairs
Issuer ticker: PPBT
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 30 Mar 2026, 16:10:12 UTC
Source filing: View source filing
Reporting owner signature: /s/ Michael Schickler

Key filing fact

Michael Schickler filed Form 3 for PURPLE BIOTECH LTD. (PPBT) on 30 Mar 2026.

Key facts

This page summarizes Michael Schickler's Form 3 filing for PURPLE BIOTECH LTD. (PPBT).
0 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 30 Mar 2026, 16:10.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002124253 Primary reporting owner

Schickler Michael

Relationship: Head of Clinical & Reg Affairs
Address: 4 OPPENHEIMER STREET, SCIENCE PARK, REHOVOT, ISRAEL
Signature: /s/ Michael Schickler
Signature date: 30 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PPBT holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,254,472
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PPBT holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 151,000
Exercise price
Footnotes: F2

PPBT holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 900,000
Exercise price
Footnotes: F3

PPBT holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 900,000
Exercise price
Footnotes: F4

PPBT holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 7,100,000
Exercise price
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Includes 6,958,334 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares

Footnote F2

Represents stock option to purchase 151,000 Ordinary Shares (equivalent to 76 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.10828125 per Ordinary Share and the option expires on April 2, 2027.

Footnote F3

Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.095054688 per Ordinary Share and the option expires on May 23, 2027.

Footnote F4

Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 393,750 Ordinary Shares are vested and exercisable, with the remaining options to purchase 506,250 Ordinary Shares vesting in equal quarterly installments until August 14, 2027.The exercise price of this stock option is $0.0115625 per Ordinary Share and the option expires on August 15, 2029.

Footnote F5

Represents stock option to purchase 7,100,000 Ordinary Shares (equivalent to 3,550 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 591,666 Ordinary Shares are vested and exercisable, with the remaining options to purchase 6,508,334 Ordinary Shares vesting in equal quarterly installments until October 21, 2028.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .